LAURI WELCH: Open Payments
NPI 1972625788 · NORTH CHELMSFORD, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$46,710 in 154 payments from 23 companies in 2025. Trend: 2023 $13,973 · 2024 $26,839 · 2025 $46,710
Speaker / faculty: $31,310Consulting: $6,015Food & beverage: $5,012Travel & lodging: $4,373
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 52 | $28,982 |
| Gilead Sciences, Inc. | 36 | $14,343 |
| Phathom Pharmaceuticals, Inc. | 7 | $1,882 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $330 |
| ABBVIE INC. | 10 | $291 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $158 |
| Lilly USA, LLC | 3 | $149 |
| NeurAxis, Inc. | 1 | $88 |
| PFIZER INC. | 3 | $67 |
| Ardelyx, Inc. | 3 | $59 |
Products named: REZDIFFRA, Epclusa, Livdelzi, VOQUEZNA, ENTYVIO, XIFAXAN, RINVOQ, DUPIXENT.
Industry payments across MA — which companies pay providers there.
